September 2009
Pharmaceutical Representative;Sep2009, Vol. 39 Issue 9, p10
The article offers news briefs related to drug clinical trials. Telik Inc. generated a positive result on the effectiveness of ezatiostat hydrochloride, Telintra, tablet in Myelodysplastic Syndrome (MDS) patients. PTC Therapeutics Inc. plans to conduct a Phase II clinical trial of the PTC299 drug in adults suffering from neurofibromatosis. QuatRx Phamaceuticals Co. has completed its second Phase III trial of its Ophena drug in patients with postmenopausal vulvovaginal atrophy.


Related Articles

  • RUMBLINGS.  // Crain's Detroit Business;1/7/2008, Vol. 24 Issue 1, p22 

    The article offers news briefs from the business sector in Detroit, Michigan. QuatRx Pharmaceutical Inc. announced positive results of its Phase III clinical trial of Ophena drug for women. Traffic and purchases on Pewabic Pottery's Web site increased after it was featured on Martha Stewart's...

  • PTC Gets $50M to Launch Ataluren, Further Studies.  // Bioworld Week;12/28/2009, Vol. 17 Issue 52, p4 

    The article reports that PTC Therapeutics Inc. in New Jersey has completed a 50 million dollars financing which will be used for the anticipated launching of a drug in Duchenne muscular dystrophy in the first half of 2011. It states that PTC also plans to use some of the funds to search other...

  • Azacitidine: A Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia. Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 17, p2501 

    Azacitidine (Vidaza®) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes...

  • Telik successfully completes FDA review.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p16 

    Reports that Telik Inc. has completed the U.S. Food and Drug Administration review of its phase III clinical trial protocol for Telcyta prodrug in non-small cell lung cancer. Analysis of the survival of patients treated with Telcyta; Role of GST P1-1 enzyme in activating Telcyta; Initiation of...

  • Running Stop Signs For A Broad-Spectrum Antigenetic. Breindl, Anette // BioWorld Today;4/24/2007, Vol. 18 Issue 79, p1 

    The article discusses the results of the Phase II clinical trials of the drug PTC124. The drug is developed to target nonsense mutations, in which a mutation changes the deoxyribonucleic acid (DNA) sequence of a protein to include an early stop codon. PTC Therapeutics Inc. chief executive...

  • Court Overrules Biotech Trial Decision. Daks, Martin C. // njbiz;8/25/2008, Vol. 21 Issue 35, p2 

    The article reports on the decision of Federal Judge William J. Martini to order PTC Therapeutics Inc. in South Plainfield, New Jersey to give an experimental drug to 16-year-old Jacob Gunvalson, who suffers from Duchenne Muscular Dystrophy, even though the firm says he does not qualify for the...

  • Baxter To Help Develop, Sell Onconova Cancer Drug.  // MondayMorning;9/24/2012, Vol. 20 Issue 36, p1 

    The article reports on the partnership between Baxter International Inc. and Onconova Therapeutics Inc. to make and market the experimental cancer drug rigosertib in Europe. It states that Onconova Therapeutics Inc. has been examining rigosertib through regulatory review and clinical testing for...

  • Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    The article offers information on the beginning of randomized phase two evaluation by Onconova Therapeutics Inc. for new oral formulation of a drug, rigosertib, to determine the efficacy of the drug in treatment of solid tumors and hematologic malignancies. The clinical study aims to determine...

  • Telik granted FDA fast track designation for Telcyta.  // PharmaWatch: Biotechnology;January 2004, Vol. 3 Issue 1, p10 

    Reports on the Fast Track designation granted by the U.S. Food and Drug Administration to Telik Inc.'s Telcyta for third line therapy for locally advanced or metastatic non-small cell lung cancer. Aim of Fast Track programs to facilitate the development and expedite the review of new drugs that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics